Insmed, Inc. $INSM Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. reduced its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 12.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 5,191 shares of the biopharmaceutical company’s stock after selling 705 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Insmed were worth $522,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Teachers Retirement System of The State of Kentucky acquired a new stake in Insmed during the 1st quarter worth about $975,000. Chung Wu Investment Group LLC acquired a new stake in Insmed during the 2nd quarter worth about $173,000. OneDigital Investment Advisors LLC grew its position in Insmed by 47.1% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company’s stock worth $399,000 after purchasing an additional 1,673 shares during the period. Caxton Associates LLP acquired a new stake in Insmed during the 1st quarter worth about $441,000. Finally, Assenagon Asset Management S.A. grew its position in Insmed by 84.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock worth $7,387,000 after purchasing an additional 33,626 shares during the period.

Insmed Price Performance

NASDAQ:INSM opened at $165.31 on Wednesday. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $168.21. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $34.94 billion, a PE ratio of -28.95 and a beta of 1.03. The stock’s 50-day moving average price is $145.35 and its 200-day moving average price is $106.37.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the previous year, the firm posted ($1.94) earnings per share. The company’s quarterly revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Melvin Md Sharoky sold 10,000 shares of Insmed stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the sale, the director directly owned 262,675 shares in the company, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of Insmed stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the completion of the sale, the insider owned 36,461 shares in the company, valued at approximately $5,303,252.45. The trade was a 67.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 152,657 shares of company stock worth $21,442,198 in the last quarter. 3.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Royal Bank Of Canada increased their price target on Insmed from $108.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. William Blair started coverage on Insmed in a research report on Wednesday, August 20th. They set an “outperform” rating on the stock. UBS Group raised their target price on Insmed from $140.00 to $194.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research report on Wednesday, October 8th. Finally, TD Cowen raised their target price on Insmed from $154.00 to $193.00 and gave the company a “buy” rating in a research report on Thursday, October 2nd. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $152.88.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.